A PHASE 1B TRIAL OF HU5F9-G4 MONOTHERAPY OR HU5F9-G4 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Contact:

NCT Number:

Protocol:

AAAR4923

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an experimental drug called Hu5F9-G4 in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This study will enroll 2 different groups of patients: Relapsed/Refractory (R/R) and Treatment-naïve Unfit (TN/U) The use of Hu5F9-G4 in this research study is experimental, which means that the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) has not approved its use for cancer treatment or treatment of any other disease.

Are you Eligible? (Inclusion Criteria)

  • Subject must be at least 18 years of age.
  • Subjects must have confirmed Relapsed/Refractory AML, MDS, or previously untreated AML.
  • Subjects must be able to understand and willingly sign a written informed consent form.

Specialty Area(s)

Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Principal Investigator

Profile Headshot
  • Director, Hematologic Malignancies Section

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032